163 related articles for article (PubMed ID: 34411614)
21. Evaluation of N-phosphonium chitosan as a novel vaccine carrier for intramuscular immunization.
Cai J; Zhang W; Xu J; Xue W; Liu Z
J Biomater Appl; 2017 Nov; 32(5):677-685. PubMed ID: 28992775
[TBL] [Abstract][Full Text] [Related]
22. Quality by Design Approach for Preparation of Zolmitriptan/Chitosan Nanostructured Lipid Carrier Particles - Formulation and Pharmacodynamic Assessment.
Awadeen RH; Boughdady MF; Meshali MM
Int J Nanomedicine; 2020; 15():8553-8568. PubMed ID: 33173292
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
Jin JW; Tang SQ; Rong MZ; Zhang MQ
Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
[TBL] [Abstract][Full Text] [Related]
24. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
[TBL] [Abstract][Full Text] [Related]
25. Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.
Watarai S; Iwase T; Tajima T; Yuba E; Kono K
ScientificWorldJournal; 2013; 2013():903234. PubMed ID: 23431260
[TBL] [Abstract][Full Text] [Related]
26. Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).
Hellfritzsch M; Christensen D; Foged C; Scherließ R; Thakur A
Int J Pharm; 2023 Dec; 648():123581. PubMed ID: 37931728
[TBL] [Abstract][Full Text] [Related]
27. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
Chen CC; Tsai TH; Huang ZR; Fang JY
Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
[TBL] [Abstract][Full Text] [Related]
28. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
29. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
Slütter B; Jiskoot W
J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
[TBL] [Abstract][Full Text] [Related]
30. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.
Heffernan MJ; Zaharoff DA; Fallon JK; Schlom J; Greiner JW
Biomaterials; 2011 Jan; 32(3):926-32. PubMed ID: 20965561
[TBL] [Abstract][Full Text] [Related]
31. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
32. Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery.
Cole H; Bryan D; Lancaster L; Mawas F; Vllasaliu D
Carbohydr Polym; 2018 Jun; 190():248-254. PubMed ID: 29628245
[TBL] [Abstract][Full Text] [Related]
33. Chitosan coated nanostructured lipid carriers (NLCs) for loading Vitamin D: A physical stability study.
Rabelo RS; Oliveira IF; da Silva VM; Prata AS; Hubinger MD
Int J Biol Macromol; 2018 Nov; 119():902-912. PubMed ID: 30063935
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders.
Yu YS; AboulFotouh K; Xu H; Williams G; Suman J; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2023 Jun; 640():122990. PubMed ID: 37127138
[TBL] [Abstract][Full Text] [Related]
35. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
36. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
37. The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.
Liu X; Wetzler LM; Massari P
Vaccine; 2008 Feb; 26(6):786-96. PubMed ID: 18191311
[TBL] [Abstract][Full Text] [Related]
38. Preparation of Modified Konjac Glucomannan Nanoparticles and their Application as Vaccine Adjuvants to Promote Ovalbumin-Induced Immune Response in Mice.
Chen N; Zhu P; Du T; Han K; Wang D; Ye J; Xiao S; Ye X; Wang Y
Pharm Res; 2018 Mar; 35(5):105. PubMed ID: 29560565
[TBL] [Abstract][Full Text] [Related]
39. Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.
Zhang Q; Yang H; Sahito B; Li X; Peng L; Gao X; Ji H; Wang L; Jiang S; Guo D
Colloids Surf B Biointerfaces; 2020 Mar; 187():110649. PubMed ID: 31767412
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
